Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) was $81.83 for the day, down -0.91% from the previous closing price of $82.58. In other words, the price has decreased by -$0.91 from its previous closing price. On the day, 1.29 million shares were traded. BMRN stock price reached its highest trading level at $83.19 during the session, while it also had its lowest trading level at $81.79.
Ratios:
Our analysis of BMRN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 85.46. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.74. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on November 15, 2023, initiated with a Overweight rating and assigned the stock a target price of $100.
On October 23, 2023, Bernstein Upgraded its rating to Mkt Perform which previously was Underperform but kept the price unchanged to $82.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 02 ’24 when Ajer Jeffrey Robert sold 5,000 shares for $82.91 per share. The transaction valued at 414,550 led to the insider holds 66,767 shares of the business.
Davis George Eric sold 1,850 shares of BMRN for $157,268 on May 02 ’24. The EVP, Chief Legal Officer now owns 56,157 shares after completing the transaction at $85.01 per share. On Apr 12 ’24, another insider, BIENAIME JEAN JACQUES, who serves as the Director of the company, sold 20,000 shares for $91.26 each. As a result, the insider received 1,825,200 and left with 474,994 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 15537881088 and an Enterprise Value of 15730230272. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 76.58, and their Forward P/E ratio for the next fiscal year is 31.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.78. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.28 while its Price-to-Book (P/B) ratio in mrq is 3.06. Its current Enterprise Value per Revenue stands at 6.364 whereas that against EBITDA is 53.601.
Stock Price History:
Over the past 52 weeks, BMRN has reached a high of $99.56, while it has fallen to a 52-week low of $76.02. The 50-Day Moving Average of the stock is -5.54%, while the 200-Day Moving Average is calculated to be -7.96%.
Shares Statistics:
BMRN traded an average of 1.53M shares per day over the past three months and 2230400 shares per day over the past ten days. A total of 188.60M shares are outstanding, with a floating share count of 186.04M. Insiders hold about 2.02% of the company’s shares, while institutions hold 98.53% stake in the company. Shares short for BMRN as of 1713139200 were 3688638 with a Short Ratio of 2.41, compared to 1710460800 on 2964290. Therefore, it implies a Short% of Shares Outstanding of 3688638 and a Short% of Float of 1.96.
